These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10602467)

  • 1. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
    Gilmore TD
    Oncogene; 1999 Nov; 18(49):6925-37. PubMed ID: 10602467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
    Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
    Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G; Gilmore TD
    Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts.
    Sif S; Capobianco AJ; Gilmore TD
    Oncogene; 1993 Sep; 8(9):2501-9. PubMed ID: 8361761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
    Nehyba J; Hrdlicková R; Bose HR
    Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
    Fan Y; Gélinas C
    Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
    Epinat JC; Dvorin EL; Gilmore TD
    Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The suppression of SH3BGRL is important for v-Rel-mediated transformation.
    Majid SM; Liss AS; You M; Bose HR
    Oncogene; 2006 Feb; 25(5):756-68. PubMed ID: 16186799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.
    Gilmore TD; Cormier C; Jean-Jacques J; Gapuzan ME
    Oncogene; 2001 Oct; 20(48):7098-103. PubMed ID: 11704834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
    Sarkar S; Gilmore TD
    Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
    Fan Y; Rayet B; Gélinas C
    Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T.
    Bhat GV; Temin HM
    Oncogene; 1990 May; 5(5):625-34. PubMed ID: 2189101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
    Starczynowski DT; Reynolds JG; Gilmore TD
    Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discreet mutations from c-Rel to v-Rel alter kappaB DNA recognition, IkappaBalpha binding, and dimerization: implications for v-Rel oncogenicity.
    Phelps CB; Ghosh G
    Oncogene; 2004 Feb; 23(6):1229-38. PubMed ID: 14961076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters.
    Gélinas C; Temin HM
    Oncogene; 1988 Oct; 3(4):349-55. PubMed ID: 2856247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNFalpha-induced cell death.
    Zong WX; Farrell M; Bash J; Gélinas C
    Oncogene; 1997 Aug; 15(8):971-80. PubMed ID: 9285692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The c-Rel transcription factor and B-cell proliferation: a deal with the devil.
    Gilmore TD; Kalaitzidis D; Liang MC; Starczynowski DT
    Oncogene; 2004 Mar; 23(13):2275-86. PubMed ID: 14755244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant rel/nfkb genes and activity in human cancer.
    Rayet B; Gélinas C
    Oncogene; 1999 Nov; 18(49):6938-47. PubMed ID: 10602468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of changes in gene expression associated with malignant transformation by the NF-kappaB family member, v-Rel.
    Petrenko O; Ischenko I; Enrietto PJ
    Oncogene; 1997 Oct; 15(14):1671-80. PubMed ID: 9349500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of v-Rel oncogene-induced inhibitor of apoptosis by differential display.
    You M; Bose HR
    Methods; 1998 Dec; 16(4):373-85. PubMed ID: 10049645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.